Epidemiology, Value Evidence & Outcomes, R&D, GlaxoSmithKline
London, United Kingdom
After training in infectious disease epidemiology and public health at the London School of Hygiene and Tropical Medicine, Marianne joined GlaxoSmithKline as a pharmacoepidemiologist supporting a range of therapeutic areas and developing an interest in post marketing non-interventional medication safety studies, specifically in vulnerable groups such as pregnant women. She moved to Novartis' Vaccines Division during the H1N1 pandemic completing several pandemic influenza vaccine safety studies taking on additional responsibility epidemiology support for maternal immunisation development programs and then leading the Epidemiology group. In 2016 she returned to GSK Pharma as an Epidemiology therapy area head and has led the teams providing support for the Infectious Diseases, Immunology and Oncology portfolios for and diverse activities from genetic epidemiology studies in support drug discovery out to post marketing safety and effectiveness studies. She is currently the Research and Safety Science Head within Epidemiology and sits on GSK's Safety Governance Board. Marianne maintains an active interest in maternal health and is the the GSK Lead for private partnership initiative, ConcePTION, establishing a new real world healthcare data network to study medication safety in pregnancy and breast feeding across Europe.
GlaxoSmithKline (Employment, Ownership Interest includes stock, stock options, patent or other intellectual property, MC is an employee of, and own shares in, GSK.)
Friday, August 26, 2022
5:15 PM – 5:30 PM CEST